Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma
Janssen-Cilag International NV has announced the submission seeking approval for an indication extension of IMBRUVICA...
AbbVie
AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline
US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...
Huahai Pharmaceutical’s Adalimumab Biosimilar Accepted by China’s CDE for Review
On December 14th, the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE)...
AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease
US-based pharmaceutical company AbbVie (NYSE: ABBV) has revealed positive top-line results from the pivotal Phase...
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...
AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...
AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all...
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...
AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...
NMPA Clears AbbVie’s ABBV-706 for Clinical Trials Targeting SCLC and Neuroendocrine Tumors
The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a...
AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...
AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...
Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie
US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm...